Tirzepatide (Zepbound, Mounjaro) Zepbound is approved to treat obesity in adults with a BMI of 30 or greater or overweight with weight-related health conditions
This study was supported by Ankang Central Hospital, Shaanxi Province (Project Numbers: Se-2023C07, AK2023-SF-11, AK2023-SFZC-11)
Unlike diet-only approaches, semaglutide addresses the biological drivers of appetite, not just willpower
Samples: 1.0, 0.3, or 0.1 g of 293 cell lysate expressing a GST-tag fusion protein
Previously Available from: 3
Lower doses and microdoses of the medication are effective for lower amounts of weight loss with a very low rate of side effects